J., Torres-Farfan, C., Reynolds, H
Notably, in high-quality large RCTs, tirzepatide demonstrated greater effectiveness than GLP-1R mono agonists in reducing serum glucose, fat mass, and body weight
PlexusDx clinicians use these markers alongside genetic insights from the Precision Peptide Genetic Test to design individualized adjustment timing and strategy
For many patients, these symptoms are mild to moderate in severity and tend to diminish over time as the body adapts to the medication
Statements These statements have not been evaluated by the Food and Drug Administration
The long-term impact on the brain is a topic of ongoing study